Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines

被引:35
作者
Chen, Jian-Li [1 ]
Wu, Xuan [1 ]
Yin, Dan [1 ]
Jia, Xiao-Hui [1 ]
Chen, Xu [1 ]
Gu, Ze-Yun [1 ]
Zhu, Xiao-Ming [1 ]
机构
[1] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China
关键词
Autophagy inhibitors; Nanomaterials; Cancer; Chemotherapy; Chemosensitization; Nanomedicines; PHASE-I TRIAL; SILVER NANOPARTICLES; ANTICANCER ACTIVITY; INDUCED APOPTOSIS; DELIVERY-SYSTEM; GRAPHENE OXIDE; CELLS; LYSOSOME; DRUG; FLUX;
D O I
10.1016/j.pharmthera.2023.108485
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Autophagy is a conserved process in which the cytosolic materials are degraded and eventually recycled for cellular metabolism to maintain homeostasis. The dichotomous role of autophagy in pathogenesis is complicated. Accumulating reports have suggested that cytoprotective autophagy is responsible for tumor growth and progression. Autophagy inhibitors, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are promising for treating malignancies or overcoming drug resistance in chemotherapy. With the rapid development of nanotechnology, nanomaterials also show autophagy-inhibitory effects or are reported as the carriers delivering autophagy inhibitors. In this review, we summarize the small-molecule compounds and nanomaterials inhibiting autophagic flux as well as the mechanisms involved. The nanocarrier-based drug delivery systems for autophagy inhibitors and their distinct advantages are also described. The progress of autophagy inhibitors for clinical applications is finally introduced, and their future perspectives are discussed.
引用
收藏
页数:19
相关论文
共 236 条
  • [1] Getting ready for building: signaling and autophagosome biogenesis
    Abada, Adi
    Elazar, Zvulun
    [J]. EMBO REPORTS, 2014, 15 (08) : 839 - 852
  • [2] Abdel Karim N.F., 2019, J. Clin. Oncol, V37, P3027, DOI [DOI 10.1200/JCO.2019.37.15_SUPPL.3027, 10.1200/JCO.2019.37.15suppl.3027, DOI 10.1200/JCO.2019.37.15SUPPL.3027]
  • [3] Lysosomal impairment-mediated autophagy dysfunction responsible for the vascular endothelial apoptosis caused by silica nanoparticle via ROS/PARP1/AIF signaling pathway
    Abulikemu, Alimire
    Zhao, Xinying
    Qi, Yi
    Liu, Yufan
    Wang, Ji
    Zhou, Wei
    Duan, Huawei
    Li, Yanbo
    Sun, Zhiwei
    Guo, Caixia
    [J]. ENVIRONMENTAL POLLUTION, 2022, 304
  • [4] A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors
    Akin, Debra
    Wang, S. Keisin
    Habibzadegah-Tari, Pouran
    Law, Brian
    Ostrov, David
    Li, Min
    Yin, Xiao-Ming
    Kim, Jae-Sung
    Horenstein, Nicole
    Dunn, William A., Jr.
    [J]. AUTOPHAGY, 2014, 10 (11) : 2021 - 2035
  • [5] Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases
    Al-Bari, Md. Abdul Alim
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (06) : 1608 - 1621
  • [6] Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
    Amaravadi, Ravi K.
    Yu, Duonan
    Lum, Julian J.
    Bui, Thi
    Christophorou, Maria A.
    Evan, Gerard I.
    Thomas-Tikhonenko, Andrei
    Thompson, Craig B.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (02) : 326 - 336
  • [7] Lys05 A new lysosomal autophagy inhibitor
    Amaravadi, Ravi K.
    Winkler, Jeffrey D.
    [J]. AUTOPHAGY, 2012, 8 (09) : 1383 - 1384
  • [8] A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer
    Anand, Kartik
    Niravath, Polly
    Patel, Tejal
    Ensor, Joe
    Rodriguez, Angel
    Boone, Toniva
    Wong, Stephen T.
    Chang, Jenny C.
    [J]. CLINICAL BREAST CANCER, 2021, 21 (03) : 199 - 204
  • [9] Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.
    Appleman, Leonard Joseph
    Normolle, Daniel Paul
    Logan, Theodore F.
    Monk, Paul
    Olencki, Thomas
    McDermott, David F.
    Ernstoff, Marc S.
    Maranchie, Jodi Kathleen
    Parikh, Rahul Atul
    Friedland, David
    Zeh, Herbert
    Liang, Xiaoyan
    Butterfield, Lisa Helene
    Lotze, Michael T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome
    Appu, Abhilash P.
    Bagh, Maria B.
    Sadhukhan, Tamal
    Mondal, Avisek
    Casey, Sydney
    Mukherjee, Anil B.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2019, 42 (05) : 944 - 954